11 Jan 2019 Research

Leukaemia: Investigating stem cells to prevent cancer

What is this research looking at?

The development of effective treatments to prevent and eradicate leukaemia requires a better understanding of the mechanisms behind malignant (harmful) transformation and disease persistence during therapy.

Importantly, leukaemia development is associated with the acquisition of abnormal metabolic features, making cancer metabolism an attractive target for new therapeutic strategies.

Metabolism is closely associated to cell functions in normal and abnormal (malignant) tissues. By measuring metabolic heterogeneity in normal tissue (haemopoietic stem cells) and in cancer (leukaemia), I will determine whether distinct cell metabolic states are functionally connected to their potential for malignant transformation and therapy resistance.

I will test if malignant transformation and therapy resistance can be prevented or attenuated by targeting their metabolic dependencies. Results from the proposed research may lead to the development of new strategies for leukaemia eradication and prevention.

What could this mean for people with leukaemia?

This project investigates the metabolic features of stem cells in a bid to find out how to prevent them turning cancerous and to reduce resistance to treatment – this may lead to the development of new strategies for leukaemia eradication and prevention.

Related posts

£200 grants for people affected by leukaemia once again available

4 April 2023

£200 grants for people affected by leukaemia once again available

Leukaemia UK and Leukaemia Care have this month relaunched the ‘Cost of Living Fund’, providing financial grants of £200 to patients with leukaemia, myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPNs),…

Leukaemia UK announces John Goldman Fellows for 2022

8 November 2022

Leukaemia UK announces John Goldman Fellows for 2022

Leukaemia UK has awarded their prestigious John Goldman Fellow research grants to four outstanding early-career researchers seeking to advance our understanding of and ability to treat blood cancer. Leukaemia UK…

Chris Dew joins Leukaemia UK as Director of Finances & Resources

31 October 2023

Chris Dew joins Leukaemia UK as Director of Finances & Resources

Leukaemia UK is delighted to announce the appointment of Chris Dew as Director of Finance & Resources, following ten years as Chief Financial Officer at musical therapy charity Nordoff-Robbins.  The…

Beloved actor who beat leukaemia now fronting charity TV ad to help raise vital funds

19 December 2023

Beloved actor who beat leukaemia now fronting charity TV ad to help raise vital funds

83-year-old actor Richard Tate will appear on screens from 26th December onwards to support Leukaemia UK’s call for legacy pledges (otherwise known as gifts in Wills), after surviving leukaemia thanks…